Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $0.31 in the last session, down -10.12% from day before closing price of $0.34. In other words, the price has decreased by -$10.12 from its previous closing price. On the day, 1.45 million shares were traded.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.64 while its Price-to-Book (P/B) ratio in mrq is 0.65.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $4.02, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -33.84%, while the 200-Day Moving Average is calculated to be -77.79%.
Shares Statistics:
A total of 58.02M shares are outstanding, with a floating share count of 49.42M. Insiders hold about 14.83% of the company’s shares, while institutions hold 34.50% stake in the company.
